Reneo Pharmaceuticals Inc. filings document the registrant's public-company reporting after a corporate transition reflected in later filings as OnKure Therapeutics, Inc. The filing record includes Form 8-K disclosures for quarterly financial results, Regulation FD corporate presentations and related exhibit materials.
The disclosures provide formal records of operating results, furnished investor communications and corporate-status context for a registrant whose earlier public identity was tied to pharmaceutical development for rare genetic mitochondrial diseases.
OnKure Therapeutics, Inc. received a joint Schedule 13G/A reporting that the named reporting persons — Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju — do not beneficially own any shares of the issuer's Class A common stock as of the reporting date. The filers state Delaware and U.S. organizational details and expressly disclaim status as a group. The filing confirms 0.0% ownership and shows no sole or shared voting or dispositive power for each reporting person, indicating they hold no economic or voting stake in the class disclosed.
OnKure Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. states that none of the Reporting Persons beneficially own any shares of OnKure common stock (CUSIP 68277Q105). The cover pages show 0 shares and 0% of the class for Perceptive Advisors, Mr. Edelman and the Master Fund, with zero sole or shared voting and dispositive power reported.
The filing confirms the Reporting Persons do not hold securities to influence control of the issuer and includes signatures by Joseph Edelman dated 08/14/2025. The issuer's principal executive office is listed in Boulder, Colorado.
Highbridge Capital Management, LLC reports holding 663,607 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 5.2% of the class based on 12,823,872 shares outstanding as of May 5, 2025. The shares are directly held by funds and accounts advised by Highbridge and Highbridge states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The Reporting Person is organized in Delaware with its principal business office at 277 Park Avenue, 23rd Floor, New York, NY, and the issuer’s principal executive offices are listed in Boulder, Colorado. The filing is signed by Kirk Rule, Executive Director, dated 08/14/2025.
Cantor Fitzgerald entities reported beneficial ownership of 669,539 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 5.2% of the outstanding shares. The percentage is calculated using 12,823,872 shares outstanding as of May 5, 2025. The filing lists four related reporting persons (Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., and CF Group Management, Inc.) that together may be deemed to beneficially own the reported shares through shared voting and dispositive power, with shared voting power and shared dispositive power of 669,539 and no sole voting or dispositive power. The filing notes a related transaction in which Howard W. Lutnick agreed to divest certain interests and agreements were entered May 16, 2025 to transfer voting shares of CF Group Management to trusts controlled by Brandon G. Lutnick; those closings remain subject to customary conditions and regulatory approvals. The statement is certified and signed by authorized officers on August 14, 2025.
OnKure Therapeutics, Inc. reported interim financials for the quarter ended June 30, 2025 reflecting operations of the combined company after a reverse recapitalization with Reneo. The company had $83.4 million in cash and cash equivalents and an accumulated deficit of $186.0 million. Management states cash is sufficient to fund the current operating plan for at least the next 12 months.
Operating results show continuing investment in drug development: R&D expense was $12.6 million in the quarter and $25.6 million for the six months, driving a six-month net loss of $31.3 million. R&D increases were driven by higher clinical trial and manufacturing costs. The company completed a $65.0 million concurrent financing at closing of the Merger and is advancing its lead candidate, OKI-219, in a Phase 1a/1b trial. The filing discloses two plaintiff complaints related to the Merger and notes the Company continues to evaluate macroeconomic and legislative tax changes.
OnKure Therapeutics, Inc. announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025. The company attached that press release as Exhibit 99.1 to this Current Report and described the release as reporting second-quarter financial results and providing a business update.
The report states that the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to the liabilities of being "filed" under the Exchange Act. The filing also shows that OnKure's Class A common stock trades as OKUR on The Nasdaq Stock Market and that the company is identified as an emerging growth company.